Oncology KnowledgeBASE

Description: This comprehensive online oncology database is a unique electronic resource for those who need to closely follow developments in oncology.

Why use a resource like Oncology KnowledgeBASE?

Unlike reports that are 'dead on arrival' OK is a constantly updated comprehensive report on every aspect of oncology drug development. To replace OK as a resource in staying informed in this sector you would need to acquire 100s of reports for thousands of dollars only to discard them as they become dated. With OK you have access to a dynamic resource for only pennies per record.

- compare results of clinical trials of drugs sharing common parameters (target, origin, drug delivery, etc.) in terms of patient/tumor profile, toxicity, response, survival, etc.

- compare protocols and interim and final results of clinical trials by specific indication (triple negative breast cancer, soft tissue sarcoma, mantle cell lymphoma, glioblastoma multiforme) by disease stage and by treatment (first line, refractory, combination regimen, adjuvant, neoadjuvant, etc.), etc.

Drugs profiled in OK

OK profiles over 4,310 drugs/in vivo imaging agents in development:

- 3,653 anticancer agents addressing over 100 cancer types and thousands of clinical indications. Of these, 1,695 are in active development; 821 have been or are currently being evaluated in clinical trials and 539 of these are targeted agents.

- 757 drugs for the management of complications of cancer and its treatment (pain, infection, mucositis, emesis, etc.)

OK also profiles over 552 marketed drugs (anticancer agents=335, adjuncts=197) globally, providing trial results from monotherapy and combination therapy trials.

In vitro testing (IVT) products

OK profiles over 200 companies and hundreds of products (screening tests, diagnostics, pharmacogenomics, prognostics, disease monitoring tests, theragnostics, etc.) in the in vitro testing area in oncology.

Enabling technologies/drug delivery

OK describes hundreds of technology platforms used to discover, evaluate, optimize, and or deliver anticancer agents such as cytotoxics, synthetic nucleic acid sequences, small molecule drugs, monoclonal antibodies, fusion proteins, etc.

Targets in oncology

OK describes over 1,000 molecular moieties that may be target candidates of anticancer strategies or used as in vitro testing markers.

Applications:

From a clinical to commercial level, OK is used for such tasks as:

- Rapid assessment of the development status of thousands of products
- Market research, due diligence and competitive assessment
- Evaluation of proposals and reports submitted by third parties
- Evaluation of R&D investments
- Education
- Rapid assessment of the development status of thousands of products
By using OK, executives can obtain an immediate assessment of the development status of:
- a group of drugs addressing a certain cancer or clinical indication, such as lung cancer, or non-small cell lung cancer (nsclc), or extended disease small-cell ling cancer, etc.
- a group of drugs by development status, i.e., drugs in phase I, II, or III clinical trials and those in preclinical or research stage
- a class of drugs acting by a well defined mechanism, such as regulating agents (inhibitors of oncogenes, receptor ligands, etc.), cytotoxics (microtubule stabilizers, DNA intercalators, immunotoxins, etc.), immunotherapeutics (therapeutic vaccines, immunomodulators, etc.)
- various technologies such as synthetic nucleic acid sequences, monoclonal antibodies, gene transfer therapy, oncolytic viruses, etc.
- novel drug delivery systems such as sustained release, depots, pulmonary delivery, vectors, etc
- thousands of protocols and interim/final results from clinical trials, by cancer and clinical indication, including dates of initiation/completion, trial locations and principle investigators/study chairs

Note: Any of the above criteria may be combined to narrow or expand a search

- Market research, due diligence and competitive assessment
By using OK, executives can assess product/company acquisition options and licensing opportunities, allowing them to design competitive strategies. OK is unique as it links products/technologies developed in-house with those being developed by others under various types of strategic alliances, to allow users to view comprehensive company pipelines. Also, global revenues are presented for major marketed oncology products to establish worldwide market opportunities.

- Evaluation of proposals/reports submitted by third parties
By using OK executives would speed up the preparation/review of proposals to perform custom projects and also ensure that the results of such assignments are representative of the status of the oncology sector in evaluation.

- Evaluation of R&D investments
By accessing OK, R&D executives are able to tap into a vast body of clinical and technological advances in this field and make informed decisions as to in-house research and collaborations with others.

- Education
Companies with expanding product lines in oncology can use OK as an educational tool for executives during reassignment or upon the introduction of new products.
Ordering:


Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct.

Product Name: Oncology KnowledgeBASE
Web Address: http://www.researchandmarkets.com/reports/3046174/
Office Code: SC

Product Format
Please select the product format and quantity you require:

Quantity
Online Access (1 Year Sub.): [ ] USD 3490

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title:  Mr [ ]  Mrs [ ]  Dr [ ]  Miss [ ]  Ms [ ]  Prof [ ]
First Name: ___________________________  Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
- Account number: 833 130 83
- Sort code: 98-53-30
- Swift code: ULSBIE2D
- IBAN number: IE78ULSB98533083313083
- Bank Address: Ulster Bank,
  27-35 Main Street,
  Blackrock,
  Co. Dublin,
  Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World